FIELD: organic chemistry, biochemistry, pharmacy.
SUBSTANCE: invention relates to parecoxib sodium salt in crystalline form that possesses properties of selective inhibitor of cyclooxygenase-2 (COX-2) and can be used in treatment of, for example, inflammatory diseases and pain. Proposed crystalline forms show characteristic peaks of powder X-roentgenogram obtained with using Cu-source of radiation and expressed as angles 2θ and chosen from groups consisting of at least values 5.6; 9.6; 11.0 and 14.5 ± 0.2 angle (form A), and 4.2; 8.3; 12.4; 16.7; 17.5; 20.8 and 24.7 ± 0.2 angle (form B), and 8.8; 11.3; 15.6; 22.4; 23.5 and 26.4 ± 0.2 angle (form E) and wherein each form is anhydrous and non-solvated. Also, invention relates to a method for preparing crystalline form A and to a pharmaceutical composition.
EFFECT: improved preparing method, valuable properties of drug.
21 cl, 5 tbl, 12 dwg, 1 sch, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DASATINIB SALTS IN CRYSTALLINE FORM | 2014 |
|
RU2662805C2 |
| SALTS AND CRYSTALLINE FORMS OF APOTTOSIS-INDUCING AGENT | 2011 |
|
RU2628560C2 |
| CO-CRYSTALLINE FORMS OF TRAMADOL AND NSAID | 2009 |
|
RU2599717C2 |
| MULTICOMPONENT CRYSTALS COMPRISING DASATINIB AND SELECTED COCRYSTAL FORMERS | 2013 |
|
RU2650524C2 |
| SOLID FORMS OF MACROLIDES | 2008 |
|
RU2476438C2 |
| N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(2-METHYLPROPYLOXY)PHENYLMETHYL) CARBAMIDE SALTS AND PREPARATION OF SAID SALTS | 2005 |
|
RU2387643C2 |
| SALTS OF DASATINIB IN AMORPHOUS FORM | 2014 |
|
RU2655435C2 |
| ABT-263 CRYSTALLINE FORMS AND SOLVATES FOR TREATMENT OF BCL-2 PROTEIN RELATED DISEASES | 2010 |
|
RU2551376C2 |
| POLYMORPHIC FORMS OF SODIUM SALT OF 4-TERT-BUTYL-N-[4-CHLORO-2-(1-OXY-PYRIDINE-4-CARBONYL)-PHENYL]-BENZENESULPHONAMIDE | 2012 |
|
RU2607191C2 |
| SOLID FORMS OF THE COMPOUND MODULATING THE KINASES | 2016 |
|
RU2730506C2 |
